Drug interactions with antianginal drugs

Abstract

Abstract: Angina pectoris is the major clinical symptom of myocardial ischemia. Angina pectoris can be managed by using drugs that either improve perfusion of the myocardium or reduce its metabolic demand. Many of the drugs used in angina pectoris are the substrate of cytochrome P450, drug interactions are easily to occur when antianginal drugs co-administrated with other drugs and foods. In this article, the drug interaction of main antianginal drugs in pharmacokinetics were reviewed, and it will help the rational use of antianginal drugs in clinical medication.

Key words: antianginal drugs, drug interaction, pharmacokinetics, cytochrome P450

CLC Number:

LI Xiao-min, GUO Xin, CHENG Ze-neng. Drug interactions with antianginal drugs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(5): 493-498.

References

1 赵梦华.硝酸酯类药物治疗稳定型心绞痛的研究现状[J].医学综述, 1999;5:237-238.
2 李必祥.基层医院应重视地高辛与其它药物的相互作用[J].现代临床医学, 2006;32:300.
3 Bolanowski J, Kobusiak-Prokopowicz M, Wegrzyn B.Interactions between propranolol, isosorbide and nitroglycerin[J].Pol Tyg Lek, 1992 ;47:1141-1142.
4 张涛.长期大量饮酒对药效的影响[J].中国社区医师( 综合版) , 2006;9:11.
5 Ishikura F, Beppu S, Hamada T, et al.Effects of sildenafil citrate( Viagra) combined with nitrate on the heart[J].Circulation,2000;102:2516.
6 Bednarcyzk EM, Furniss SM, Green JA, et al.Evaluation of the indomethacin-nitroglycerin interaction with positron-emission tomography[J].J Cardiovasc Pharmacol, 1997;30:731-733.
7 Harder S, Thurmann P.Clinically important drug interactions with anticoagulants.An update [J].Clin Pharmacokinet, 1996 ;30:416-444.
8 Harder S, Klinkhardt U.Thrombolytics:drug interactions of clinical significance[J].Drug Saf, 2000;23:391-399.
9 潘云, 曹善萍.卡托普利与其他药物的相互作用[J].中国民康医学, 2006;18:545-546.
10 周茂金, 梅任奎, 苏美英.影响地高辛血药浓度的药物[J].华西药学杂志, 1994;9:111-114.
11 李静, 钱莉, 吕迁洲.与细胞色素P450 酶系介导相关的常用心血管药物相互作用[J].中国药房, 2006;17:1179-1181.
12 Kovarik JM, Beyer D, Bizot MN, et al.Pharmacokinetic interaction between verapamil and everolimus in healthy subjects[J].Br J Clin Pharmacol, 2005;60:434-437.
13 Kovarik JM, Beyer D, Schmouder RL.Everolimus drug interactions: application of a classification system for clinical decision making[J].Biopharm Drug Dispos, 2006;27:421-426.
14 Jacobson TA.Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors[J].Am J Cardiol, 2004 ;94:1140-1146.
15 Lamberg TS, Kivisto KT, Neuvonen PJ.Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone[J].Clin Pharmacol Ther, 1998;63:640-645.
16 黄林清, 周世文, 周素琴, 等.维拉帕米对硫唑嘌呤代谢物6-巯嘌呤药动学的影响[J].华西药学杂志, 2001 ;16:31-33.
17 Bailey DG, Dresser GK.Interactions between grapefruit juice and cardiovascular drugs[J].Am J Cardiovasc Drugs, 2004 ;4:281-297.
18 诸敏, 姚彤炜, 曾苏.银杏黄酮的体外葡醛酸反应及其药物相互作用[J].浙江大学学报( 医学版) , 2004 ;33:15-20.
19 Grundy JS, Foster RT.The nifedipine gastrointestinal therapeutic system ( GITS).Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties[J].Clin Pharmacokinet,1996;30:28-51.
20 史文石, 邢凤玲, 李宝清.西咪替丁与配伍用药物的相互作用[J].中国医药导报, 2006 ;3:96-97.
21 Nishio S, Watanabe H, Kosuge K.Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension[J].Hypertens Res, 2005 ;28:223-227.
22 Glesby MJ, Aberg JA, Kendall MA.Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers[J].Clin Pharmacol Ther, 2005;78:143-153.
23 Varhe A, Olkkola KT, Neuvonen PJ.Diltiazem enhances the effects of triazolam by inhibiting its metabolism[J].Clin Pharmacol Ther, 1996 ;59:369-375.
24 Sawada T, Sako K, Yoshihara K, et al.Timed-release formulation to avoid drug-drug interaction between diltiazem and midazolam[J].J Pharm Sci, 2003;92:790-797.
25 Kazuhiro K, Yang J, HiroshiW, et al.Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status[J].Drug Metab Dispos, 2001;29:1284-1289.
26 Azie NE, Brater DC, Becker PA, et al.The interaction of diltiazem with lovastatin and pravastatin[J].Clin Pharmacol Ther, 1998 ;64:369-377.
27 Choi JS, Piao YJ, Han HK.Pharmacokinetic interaction between fluvastatin and diltiazem in rats[J].Biopharm Drug Dispos, 2006;27:437-441.
28 Christensen H, Asberg A, Holmboe AB, et al.Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers[J].Eur J Clin Pharmacol, 2002;58:515-520.
29 Bottiger Y, Sawe J, Brattstrom C, et al.Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers[J].Clin Pharmacol Ther, 2001 ;69:32-40.
30 Alderman CP, Hundertmark JD, Soetratma TW.Interaction of serotonin re-uptake inhibitors with perhexiline[J].Aust N Z J Psychiatry , 1997;31:601-603.
31 Saranteas T, Mourouzis C, Koumoura F, et al.Effects of propranolol or paracetamol on lidocaine concentrations in serum and tissues[J].J Oral Maxillofac Surg , 2003;61:604-607.
32 Vercruysse I, Massart DL, Dupont AG.Increase in plasma propranolol caused by nicardipine is dependent on the delivery rate of propranolol[J].Eur J Clin Pharmacol, 1995 ;49:121-125.
33 戈升荣, 施安国, 王平全.尼索地平包衣片与某些药物的相互作用[J].中国医院药学杂志, 2000 ;20:675-676.
34 Goldberg MR, Sciberras D, De Smet MD, et al.Influence ofβ-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B 1D agonist:differential effects of propranolol, nadolol and metoprolol[J].Br J Clin Pharmacol, 2001;52:69-76.
35 Rolan P.Potential drug interactions with the novel antimigraine compound zolmitriptan ( Zomig, 311C90) [J].Cephalalgia,1997 ;17:21-27.
36 Bauer LA, Horn JR, Maxon MS, et al.Effect of metoprolol and verapamil administered separately and concurrently after single doses on liver blood flow and drug disposition[J].J Clin Pharmacol, 2000;40:533-543.
37 曲福军, 张雪娟, 宋力, 等.美多洛尔与卡托普利在健康人体内的药代动力学相互作用[J].中国药学杂志,2001 ;36:111-113.
38 Hemeryck A, Lefebvre RA, De Vriendt C, et al.Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers[J].Clin Pharmacol Ther, 2000;67:283-291.
39 朱立勤, 娄建石.细胞色素P450 与药物代谢的研究现状[J].中国临床药理学与治疗学, 2004;9:1081-1086.
40 Somer M, Kallio J, Pesonen U, et al.Influence of hydroxychloroquine on the bioavailability of oral metoprolol[J].Br J Clin Pharmacol, 2000;49:549-554.
41 Hamelin BA, Bouayad A, Methot J, et al.Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity[J].Clin Pharmacol Ther, 2000;67:466-477.
42 Sharma A, Pibarot P, Pilote S, et al.Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women[J].J Pharmacol Exp Ther, 2005 ;313:1172-1181.
43 Werner U, Werner D, Rau T, et al.Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans[J].Clin Pharmacol Ther, 2003;74:130-137.
44 Lilja JJ, Raaska K, Neuvonen PJ.Effects of orange juice on the pharmacokinetics of atenolol[J].Eur J Clin Pharmacol, 2005;61:337-340.
45 黄佳.抗凝药物的相互作用与合理用药[J].继续医学教育, 2006 ;20:30-33.
46 Verstuyft C, Strabach S, El-Morabet H, et al.Dipyridamole enhances digoxin bioavailability via P-gly coprotein inhibition[J].Clin Pharmacol Ther, 2003 ;73:51-60.
47 Babaoglu MO, Karadag O, Saikawa Y, et al.Hepatotoxicity due to a possible interaction between cytosine arabinoside and dipyridamole:a case report[J].Eur J Clin Pharmacol, 2004;60:455-456.
48 De La Cruz JP, Blanco E, Sanchez de la Cuesta F.Effect of dipyridamole and aspirin on the platelet-neutrophil interaction via the nitric oxide pathway[J].Eur J Pharmacol, 2000;397: 35-41.

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[3]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[4]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[5]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[6]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[7]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[8]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[9]	ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi. Interactions and clinical significance of gut microbiota and levothyroxine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314.
[10]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[11]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[12]	MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
[13]	HE Xueru, FU Yuhao, XUN Xuejiao, CUI Yanjun, DONG Zhanjun. Advances in uridine diphosphate glucuronosyltransferase-mediated drug interactions with tyrosine kinase inhibitors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 936-945.
[14]	DAI Jingyi, WANG Jingjing, ZHANG Jing, YU Jicheng, LI Nanyang, HUANG Zhiwei. Clinical application and research progress of inhaled methoxyflurane [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 808-813.
[15]	PAN Shu, WU Yijin, ZHANG Sasa, WANG Qihai, LUO Tingting, YIN Qin. Pharmacokinetics of methotrexate mediated by organic anion transporter 3 in adjuvant induced arthritis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 516-525.